ALT Altimmune Inc

Altimmune Statement on the Passing of Dr. Stephen Harrison

Altimmune Statement on the Passing of Dr. Stephen Harrison

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing.

Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.

Contact:

Rich Eisenstadt

Chief Financial Officer

Phone: 240-654-1450



EN
25/04/2024

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces First Quarter 2024 Financial Results and Provides ...

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and prov...

May 9, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The sessions will be webcast and can be accessed b...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report First Quarter 2024 Financial Results and Provide B...

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at . Participants who woul...

May 2, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate at Two Upcoming Conferences

Altimmune to Participate at Two Upcoming Conferences GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA)    Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease...

May 1, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Statement on the Passing of Dr. Stephen Harrison

Altimmune Statement on the Passing of Dr. Stephen Harrison GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, chari...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch